Hot off the presses - New publication gives more details about the results of Ionis and Roche's safety study with a Huntingtin-lowering ASO
Multiple teams find small differences in the 'CAG repeat' bit of the Huntington's disease gene. They don't directly change the huntingtin protein, but do alter the age of symptom onset. What's behind this enigma and what does it mean for patients?
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
HDSA's frequently asked questions factsheet about the huntingtin-lowering trial ASO program was so good we stole it (with permission)
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
CRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
Pfizer announces the 'Amaryllis' trial of a PDE-10 inhibitor drug failed to improve symptoms of HD